AKTTHR308 as a marker of PI3K activation was measured in cells from a subset of chronic lymphocytic leukaemia patients with circulating lymphocytes and was observed to be reduced by >90% following dosing, demonstrating target inhibition. Here, PIK3CA is linked to B-cell chronic lymphocytic leukemia.